Adrian Krainer Sells 40,472 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Adrian Krainer sold 40,472 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $26.98, for a total transaction of $1,091,934.56. Following the sale, the director owned 364,246 shares in the company, valued at $9,827,357.08. This represents a 10.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Stoke Therapeutics Price Performance

Shares of STOK opened at $28.48 on Thursday. The business has a 50-day moving average of $27.33 and a 200-day moving average of $18.14. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of 42.51 and a beta of 1.32. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The firm had revenue of $10.63 million for the quarter, compared to analyst estimates of $6.06 million. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on STOK. BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. JPMorgan Chase & Co. lifted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Monday, November 3rd. Chardan Capital restated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Wedbush raised their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Finally, Canaccord Genuity Group boosted their price target on Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after purchasing an additional 217,616 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Stoke Therapeutics by 7.9% in the 2nd quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after buying an additional 168,771 shares during the last quarter. Siren L.L.C. raised its position in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock valued at $14,945,000 after buying an additional 247,347 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after acquiring an additional 293,072 shares during the last quarter. Finally, Polar Capital Holdings Plc grew its position in Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after acquiring an additional 439,824 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.